skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 
Home » UK Shares » Three Quick Facts » Three Quick Facts: Marstons, Oxford Biodynamics and N4 Pharma

Here are three things you need to know in the financial markets this morning from investment writer, Tony Cross.

#1. COVID hits Marstons performance pre-Christmas

Slim pickings this morning, but Marstons [LON:MARS] has published a trading update for the 16 weeks to 12th January. Like-for-like ales were down 3.9% against FY 19, reflecting weaker consumer sentiment and the change in consumer behaviour as a result of the emergence of the Omicron variant. The company does however note that performance within the M25 was significantly worse than elsewhere, most notably in the five weeks before Christmas. Costs remain in control and there’s confidence that changes in COVID regulations will now allow some normality to return to the market. An AGM is held today and interim results are expected in the second half of May.

#2. Rough ride for Oxford Biodynamics as it shifts stance

AIM-listed Oxford Biodynamics [LON:OBD] has published full year results today. The company is in the midst of a transition onto a commercial trajectory apparently, presenting a series of challenges which were exacerbated by the COVID pandemic. A string of operational highlights are listed, but if investors are looking at the financials they make for a rough read. Revenues have fallen by 40%, losses are up and cash has been depleted, falling from £11.5m to £4.3m at 30th September.

#3. N4 Pharma joins government backed accelerator

N4 Pharma [LON:N4P], again on the AIM Market, has issued a works update on its oncology programme. Positive results as announced mid-December have allowed the company to join a government backed medical accelerator, which whilst not offering any guarantee of success, will lift the profile of the company. The detail in the note is very technical, but it’s difficult not to see this as a positive.


This article is not investment advice. Investors should do their own research or consult a professional advisor.

Tony Cross

Tony Cross

Tony Cross is a market commentator with over 15 years of experience, producing compelling, insightful copy for journalists and investors alike. Focusing on macroeconomics, UK blue chip equities and inter market analysis, Cross's commentary is well regarded for its clarity and ability to cut through the waffle. He has been quoted in publications as diverse as The Financial Times, The Times, The Guardian and The Sun. He has also been a regular guest on both Share Radio and TipTV.

Stocks in Focus

Here are some of the smaller companies we follow most closely. They represent significant growth stories in our view. Our in-depth reports detail why we like them.


Subscribe for more stories like this, 8am weekdays - for free!

Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Back To Top